Proportion of sporadic ovarian/HGS and sporadic breast cancer/triple negative with BRCA1/2 mutations
| Age of diagnosis | Sporadic ovarian | Sporadic HGS ovarian | Sporadic breast cancer | Sporadic TNT | |
| <30 | Mutation | 0 | 0 | 5 | 4 |
| Number tested | 6 | 2 | 80 | 26 | |
| BRCA1/2 | % | 0.0 | 0.0 | 6.25 | 15.4 |
| 30–39 | Mutation | 1 | 1 | 7 | 4 |
| Number tested | 12 | 8 | 179 | 87 | |
| % | 8.3 | 12.5 | 3.9 | 4.6 | |
| 40–49 | Mutation | 5 | 5 | 2 | 2 |
| Number tested | 51 | 43 | 54 | 24 | |
| % | 9.8 | 11.6 | 3.7 | 8.3 | |
| 50–59 | Mutation | 9 | 9 | 1 | 1 |
| Number tested | 64 | 60 | 24 | 4 | |
| % | 14.1 | 15.0 | 4.2 | 25.0 | |
| 60+ | Mutation | 0 | 0 | 0 | 0 |
| Number tested | 18 | 16 | 3 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total mutated | 15 | 15 | 15 | 11 | |
| Total tested | 151 | 129 | 340 | 142 | |
| % | 9.9 | 11.6 | 4.4 | 7.75 | |
| BRCA1 | 11 | 11 | 10 | 10 | |
| % | 7.28 | 8.5 | 2.9 | 7.0 | |
| BRCA2 | 4 | 4 | 5 | 1 | |
| % | 2.65 | 3.1 | 1.5 | 0.7 | |
2/8 adopted patients with triple-negative breast cancer with BRCA1 mutations were excluded from the analysis.
HGS, high-grade serous; TNT, triple-negative tumour.